Federal Register / Vol. 70, No.
130 / Friday, July 8, 2005 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Sensory
SBIRs.
Date: July 27, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Chemoprevention of Lung Cancer.
Date: July 29, 2005.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Eun Ah Cho, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
MSC 7804, Bethesda, MD 20892, (301) 451–
4467, choe@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 29, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–13464 Filed 7–7–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Method for Diagnosis of
Atherosclerosis
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license worldwide to practice the
invention embodied in: Provisional
Patent Application Serial No. 60/
607,031 filed 9/3/2004, and Provisional
Patent Application Serial No. 60/
618,275 filed 10/12/2004 titled ‘‘Method
for Diagnosis of Atherosclerosis’’
VerDate jul<14>2003 16:32 Jul 07, 2005 Jkt 205001
39525
referenced at HHS as E–276–2004/0–
US–01 and E–276–2004/0–US–01
respectively to Biosite, Inc., having a
place of business in the state of
California. The field of use may be
limited to an FDA approved clinical
diagnostic product for atherosclerosis.
The United States of America is the
assignee of the patent rights in this
invention. The territory may be
worldwide. This announcement is the
first notice to grant an exclusive license
to this technology.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
September 6, 2005 will be considered.
ADDRESSES: Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Fatima Sayyid, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4521; Facsimile:
(301) 402–0220; e-mail:
sayyidf@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
subject provisional patent applications
are related to the field of vascular
disease and markers expressed in
peripheral blood or secreted into serum.
Specifically, the claims are directed to
a method of diagnosing atherosclerosis
or determining the progression of
atherosclerosis in a subject by assaying
the expression of FOS, DUSP1, or both
FOS and DUSP1 in monocytes from the
subject wherein an increased expression
of either or both markers indicates
atherosclerosis or severity of
atherosclerosis in a subject.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\08JYN1.SGM
Dated: June 30, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–13460 Filed 7–7–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Heat Induced Gene
Expression to Treat Cancer
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Provisional Patent
Application Serial No. 60/024,213,
entitled ‘‘Spatially And Temporal
Control Of Gene Expression Using A
Heat Shock Protein Promoter In
Combination With Local Heat’’ filed
August 15, 1996 (E–235–1995/0–US–
01), and all related foreign patents/
patent applications, to New England
OncoTherapeutics, Inc., having a place
of business in Cambridge,
Massachusetts. The patent rights in
these inventions have been assigned to
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to gene-
based therapeutics which incorporate
focused ultrasound heating technologies
to treat cancer.
DATES: Only written comments and/or
license applications that are received by
the National Institutes of Health on or
before September 6, 2005 will be
considered.
ADDRESSES: Requests for copies of the
patent, inquiries, comments and other
materials relating to the contemplated
exclusive license should be directed to:
George G. Pipia, Ph.D., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5560; Facsimile:
(301) 402–0220; E-mail:
pipiag@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
above-mentioned patent application
describes methods of using heat to
08JYN1